| scholarly article | Q13442814 |
| review article | Q7318358 |
| P2093 | author name string | Mikkael A Sekeres | |
| Hien K Duong | |||
| P2860 | cites work | CD33 expression and P-glycoprotein-mediated drug efflux inversely correlate and predict clinical outcome in patients with acute myeloid leukemia treated with gemtuzumab ozogamicin monotherapy | Q24678297 |
| Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia | Q27851430 | ||
| Low-dose cytarabine versus intensive chemotherapy in the treatment of acute nonlymphocytic leukemia in the elderly | Q68700843 | ||
| Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study | Q73292530 | ||
| Therapeutic options and treatment results for patients over 75 years of age with acute myeloid leukemia | Q74459345 | ||
| Differences in CD33 intensity between various myeloid neoplasms | Q78360878 | ||
| A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment | Q79812026 | ||
| Combination therapy with arsenic trioxide, all-trans retinoic acid, and gemtuzumab ozogamicin in recurrent acute promyelocytic leukemia | Q79839629 | ||
| Adding low-dose gemtuzumab ozogamicin to fludarabine, Ara-C and idarubicin (MY-FLAI) may improve disease-free and overall survival in elderly patients with non-M3 acute myeloid leukaemia: results of a prospective, pilot, multi-centre trial and compa | Q80530384 | ||
| Impact of remission induction chemotherapy on survival in older adults with acute myeloid leukemia | Q80855046 | ||
| Gemtuzumab ozogamicin (Mylotarg) as single-agent treatment for frail patients 61 years of age and older with acute myeloid leukemia: final results of AML-15B, a phase 2 study of the European Organisation for Research and Treatment of Cancer and Grup | Q81004098 | ||
| Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse | Q28204295 | ||
| Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461) | Q28209814 | ||
| Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B | Q28247684 | ||
| The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties | Q28283156 | ||
| Gemtuzumab ozogamicin for relapsed and refractory acute myeloid leukemia and myeloid sarcomas | Q33361455 | ||
| Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence | Q33368039 | ||
| High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: a prospective study of the alfa group | Q33373033 | ||
| A double-blind placebo-controlled trial of granulocyte colony-stimulating factor in elderly patients with previously untreated acute myeloid leukemia: a Southwest oncology group study (9031). | Q33502338 | ||
| Postremission therapy in older patients with de novo acute myeloid leukemia: a randomized trial comparing mitoxantrone and intermediate-dose cytarabine with standard-dose cytarabine | Q34516512 | ||
| The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial | Q34517235 | ||
| Outcome after induction chemotherapy for older patients with acute myeloid leukemia is not improved with mitoxantrone and etoposide compared to cytarabine and daunorubicin: a Southwest Oncology Group study | Q34528336 | ||
| Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia | Q34536382 | ||
| A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group | Q34542232 | ||
| Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia | Q34563645 | ||
| Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients | Q34597777 | ||
| Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. Cancer and Leukemia Group B. | Q34722375 | ||
| Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. | Q34753320 | ||
| The role of drug efflux pumps in acute myeloid leukemia. | Q34769834 | ||
| On the value of intensive remission-induction chemotherapy in elderly patients of 65+ years with acute myeloid leukemia: a randomized phase III study of the European Organization for Research and Treatment of Cancer Leukemia Group | Q35155166 | ||
| Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy--the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organiz | Q36895799 | ||
| Phase II pilot trial of gemtuzumab ozogamicin (GO) as first line therapy in acute myeloid leukemia patients age 65 or older | Q40521174 | ||
| Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti-CD33 calicheamicin immunoconjugate | Q40638371 | ||
| Impact of age and gender on the pharmacokinetics of gemtuzumab ozogamicin | Q42661451 | ||
| Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial | Q43718516 | ||
| Experience with gemtuzumab ozogamycin ("mylotarg") and all-trans retinoic acid in untreated acute promyelocytic leukemia | Q43993658 | ||
| Gemtuzumab ozogamicin with or without interleukin 11 in patients 65 years of age or older with untreated acute myeloid leukemia and high-risk myelodysplastic syndrome: comparison with idarubicin plus continuous-infusion, high-dose cytosine arabinosi | Q44010377 | ||
| Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720. | Q44083625 | ||
| Mylotarg combined with topotecan and cytarabine in patients with refractory acute myelogenous leukemia | Q44228944 | ||
| Pilot study of Mylotarg, idarubicin and cytarabine combination regimen in patients with primary resistant or relapsed acute myeloid leukemia | Q44259317 | ||
| Differential response of human acute myeloid leukemia cells to gemtuzumab ozogamicin in vitro: role of Chk1 and Chk2 phosphorylation and caspase 3. | Q44308345 | ||
| Gemtuzumab ozogamicin, fludarabine, cytarabine and cyclosporine combination regimen in patients with CD33+ primary resistant or relapsed acute myeloid leukemia | Q44512469 | ||
| Hydroxyurea, azacitidine and gemtuzumab ozogamicin therapy in patients with previously untreated non-M3 acute myeloid leukemia and high-risk myelodysplastic syndromes in the elderly: results from a pilot trial | Q46236663 | ||
| Long-term disease-free survival after gemtuzumab, intermediate-dose cytarabine, and mitoxantrone in patients with CD33(+) primary resistant or relapsed acute myeloid leukemia. | Q46317190 | ||
| The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis | Q46580597 | ||
| Gemtuzumab ozogamicin plus cytarabine in elderly patients with relapsed or refractory acute myeloid leukaemia | Q46676396 | ||
| Comparative efficacy and safety of gemtuzumab ozogamicin monotherapy and high-dose cytarabine combination therapy in patients with acute myeloid leukemia in first relapse | Q46752386 | ||
| Gemtuzumab ozogamicin, cytosine arabinoside, G-CSF combination (G-AraMy) in the treatment of elderly patients with poor-prognosis acute myeloid leukemia. | Q46974006 | ||
| Gemtuzumab ozogamicin (Mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemia | Q47371912 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial 3.0 Unported | Q18810331 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | leukemia | Q29496 |
| carbohydrate | Q11358 | ||
| antineoplastic | Q2853144 | ||
| monoclonal antibody | Q422248 | ||
| blood proteins | Q425056 | ||
| acute myeloid leukemia | Q264118 | ||
| globulins | Q321710 | ||
| P304 | page(s) | 197-205 | |
| P577 | publication date | 2009-05-14 | |
| P1433 | published in | Clinical Interventions in Aging | Q5133768 |
| P1476 | title | Targeted treatment of acute myeloid leukemia in older adults: role of gemtuzumab ozogamicin | |
| P478 | volume | 4 |
| Q47114983 | Identifying biomarkers of breast cancer micrometastatic disease in bone marrow using a patient-derived xenograft mouse model |
| Q46612829 | Immune responses and long-term disease recurrence status after telomerase-based dendritic cell immunotherapy in patients with acute myeloid leukemia. |
| Q37810123 | Immunotherapy with histamine dihydrochloride for the prevention of relapse in acute myeloid leukemia |
| Q84220239 | Induction of DNA strand breaks is critical to predict the cytotoxicity of gemtuzumab ozogamicin against leukemic cells |
| Q34756337 | Innovative proteomics for the discovery of systemically accessible cancer biomarkers suitable for imaging and targeted therapies |
| Q36979140 | Target Therapy in Hematological Malignances: New Monoclonal Antibodies. |
| Q42127880 | The complete 12 Mb genome and transcriptome of Nonomuraea gerenzanensis with new insights into its duplicated "magic" RNA polymerase |
Search more.